Navigation Links
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled 'Bipolar Trans Carotenoid Salts and Their Uses,' for Its Family of First-In-Class Molecules
Date:4/8/2008

CHARLOTTESVILLE, Va., April 8, 2008 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing drugs utilizing a novel method of action that enhances oxygen diffusion, today announced that it has been granted U.S. patent no. 7,351,844 entitled "Bipolar Trans Carotenoid Salts and Their Uses." This patent includes claims to a family of first-in-class new chemical entities, known as trans biopolar carotenoid (or TBC) molecules. In addition, the Company also announced it has been granted corresponding patents from the South African and the New Zealand Patent Offices.

"The issuance of these patents is a vital step in our intellectual property development strategy, furthering our goal of bringing Diffusion Pharmaceutical's first-in-class therapeutics to market. Our highly unique compounds may one day treat patients with a broad range of disorders involving hypoxia," said David G. Kalergis, Diffusion's CEO.

In addition to these newly issued patents, the Company has also filed other U.S. patent applications and numerous corresponding foreign and national-stage applications in major international markets.

About Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen deprived (hypoxic) tissue. Potential clinical applications include cancer, critical care uses such as trauma, hemorrhage, stroke and heart attack, as well as chronic conditions such as peripheral arterial and vascular disease, cardiovascular disease, and respiratory disorders. Enhanced diffusion of oxygen into hypoxic tissue has an important application in oncology by improving the efficacy of radiation therapy in cancerous tumors. A Phase 1 study for its lead molecule, trans sodium crocetinate (TSC), in healthy subjects was successfully completed in 2007. The company is now initiating proof-of-concept and dose-finding studies in cancer patients undergoing radiation therapy and in peripheral arterial disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit http://www.diffusionpharma.com.


'/>"/>
SOURCE Diffusion Pharmaceuticals LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
2. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
3. Microbia Announces Name Change to Ironwood Pharmaceuticals
4. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
5. Memory Pharmaceuticals Receives Nasdaq Notification
6. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
7. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
8. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
9. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
10. VIA Pharmaceuticals Complies With NASDAQ Rule
11. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ON (PRWEB) , ... May 05, 2016 , ... ... following the previously announced identification of its first three targets, it has identified ... misfolded Amyloid beta (Aß), implicated in the development and progression of Alzheimer’s disease ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... ... Well, look no further than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. Offering ... need to give mom an experience she won’t forget. , Guests that visit ...
(Date:5/4/2016)... , May 4, 2016  Bayer today ... oncology compound Stivarga ® (regorafenib) tablets for ... (HCC) has met its primary endpoint of a ... called RESORCE, evaluated the efficacy and safety of ... progressed after treatment with sorafenib. The safety and ...
(Date:5/4/2016)... New York , May 4, 2016 ... by Transparency Market Research "Metabolomics Market - Global Industry ... 2024", the metabolomics market is anticipated to expand at ... reach USD 2,494.8 million by 2024. Metabolomics ... as metabolites, within cells, biofluids, tissues or organisms. Together, ...
Breaking Biology Technology:
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
Breaking Biology News(10 mins):